10-K: Alumis Reports Positive Phase 3 Envu Data, Secures $300M ATM Facility

Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envu in plaque psoriasis, while also securing a $300 million at-the-market equity offering facility.

Summary

• Alumis Inc. is a clinical-stage biopharmaceutical company focused on immune-mediated diseases, primarily developing Tyrosine Kinase 2 (TYK2) inhibitors (envu, A-005) and lonigutamab.
• Reported positive topline results from Phase 3 ONWARD1 and ONWARD2 global clinical trials for envu in moderate-to-severe plaque psoriasis (PsO) in the first quarter of 2026, meeting all primary and secondary endpoints with high statistical significance (p < 0.0001).
• On average across both ONWARD1 and ONWARD2, 74% of patients achieved Psoriasis Area and Severity Index (PASI) 75 and 59% achieved static Physicians Global Assessment (sPGA) 0/1 at Week 16.
• Rapid responses were observed, with clear separation from placebo on PASI 90 as early as Week 4.
• At Week 24, approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100, on average across both trials.
• Envu also achieved superior skin clearance compared with apremilast on all PASI endpoints at Week 24.
• The safety profile of envu was consistent with the Phase 2 trial, generally well-tolerated, with the majority of treatment-emergent adverse events (TEAEs) being mild-to-moderate, transient, and responding to standard therapy. No safety signals were observed.
• Plans to submit a New Drug Application (NDA) for envu in PsO to the FDA in the second half of 2026.
• Envu is currently being evaluated in a Phase 2 clinical trial (LUMUS) for systemic lupus erythematosus (SLE), with topline results expected in the third quarter of 2026.
• A-005, a CNS-penetrant allosteric TYK2 inhibitor, initiated its Phase 1 program in healthy volunteers in April 2024 and reported positive initial results in December 2024, showing it was well tolerated with no serious adverse events (SAEs) reported.
• Acquired lonigutamab, a subcutaneously delivered, monoclonal antibody targeting IGF-1R for the potential treatment of Thyroid Eye Disease (TED), through the ACELYRIN Merger in May 2025.
• Entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. on March 18, 2026, to sell up to $300.0 million of common stock through an at-the-market equity offering.
• Net loss for the year ended December 31, 2025, was $243.3 million, an improvement from $294.2 million in 2024.
• The accumulated deficit as of December 31, 2025, was $901.9 million.
• Cash, cash equivalents, and marketable securities totaled $308.5 million as of December 31, 2025.
• Received net proceeds of $324.4 million from a public offering of common stock that closed on January 9, 2026.
• Recognized a gain on bargain purchase of $187.9 million from the ACELYRIN Merger in May 2025.
• Entered into a collaboration agreement with Kaken Pharmaceutical Co., Ltd. in March 2025, receiving an upfront payment of $20.0 million and up to $20.0 million for global development costs through 2026.
• Experienced an ownership change under Section 382 of the Internal Revenue Code, resulting in the expiration of U.S. federal net credits before utilization and a reduction of deferred tax assets.
• Alumis assumed liabilities for a purported federal securities class action lawsuit against ACELYRIN, alleging misleading disclosures about a Phase 2b trial of izokibep.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to the highly significant positive Phase 3 clinical trial results for envu in psoriasis, which is a major de-risking event, coupled with successful capital raises that strengthen the company's financial position for continued development.

Positives

• Positive topline results from Phase 3 ONWARD1 and ONWARD2 trials for envu in plaque psoriasis, meeting all primary and secondary endpoints with high statistical significance (p < 0.0001).
• High rates of skin clearance observed: 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1 at Week 16 (average across both trials).
• Responses deepened over time, with approximately 65% achieving PASI 90 and over 40% achieving PASI 100 at Week 24.
• Rapid responses were observed, with clear separation from placebo on PASI 90 as early as Week 4.
• Envu demonstrated superior skin clearance compared with apremilast on all PASI endpoints at Week 24.
• The safety profile of envu was consistent with the Phase 2 trial, generally well-tolerated, with the majority of AEs being mild-to-moderate and no new safety signals observed.
• Positive initial data from the Phase 1 clinical trial of A-005 in healthy participants, showing it was well tolerated with no SAEs reported.
• Strategic acquisition of ACELYRIN in May 2025, adding lonigutamab to the development portfolio and strengthening the balance sheet and cash position.
• Recognized a significant gain on bargain purchase of $187.9 million from the ACELYRIN Merger.
• Secured substantial additional financing: $324.4 million net proceeds from a public offering in January 2026 and a $300.0 million at-the-market equity offering facility with Cantor Fitzgerald & Co.
• Entered into a collaboration agreement with Kaken Pharmaceutical Co., Ltd. for envu in Japan, including an upfront payment of $20.0 million and up to $20.0 million for global development costs through 2026.
• Net loss decreased to $243.3 million in 2025 from $294.2 million in 2024.

Negatives

• Incurred substantial losses since inception, with an accumulated deficit of $901.9 million as of December 31, 2025.
• Expects to incur significant and increasing losses for the foreseeable future, requiring substantial additional financing.
• Discontinued the proof-of-concept Phase 2a clinical trial of envu in non-infectious uveitis in June 2024 due to efficacy results not meeting the clinical threshold for success.
• Alumis assumed liabilities for a purported federal securities class action lawsuit against ACELYRIN, alleging misleading disclosures about a Phase 2b trial of izokibep in hidradenitis suppurativa.
• Experienced an ownership change under Section 382 of the Internal Revenue Code, resulting in the expiration of U.S. federal net credits before utilization and a reduction of deferred tax assets.
• The EU Committee for Medicinal Products for Human Use (CHMP) provided comments on the length of the two pivotal 24-week Phase 3 trials for envu, which may delay EU regulatory approval and require substantially more resources.
• Climb Bio, Inc. filed a complaint seeking a declaratory judgment that budoprutug is not a Product under the Purchase Agreement, and Alumis issued a notice of material breach for a $3.0 million development milestone payment, indicating a potential dispute over revenue.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, and has incurred substantial losses since its inception and anticipates incurring substantial and increasing losses for the foreseeable future.
• Enrollment and retention of participants in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside the company's control, including difficulties in identifying patients, the availability of competitive products and significant competition for recruiting participants in clinical trials.
• The company will require substantial additional financing to achieve its goals, and failure to obtain additional capital when needed, or on acceptable terms, could cause it to delay, limit, reduce or terminate its product development or future commercialization efforts.
• Preclinical and clinical development involves a lengthy and expensive process, with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. The company may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of its current or any future product candidates.
• Clinical trials may reveal serious adverse events (SAEs) and significant adverse events (AEs) not seen in preclinical studies or prior clinical trials, potentially resulting in a safety or tolerability profile that could delay or prevent regulatory approval or market acceptance of envu, A-005, or any future product candidates.
• The company faces intense competition from entities that have made substantial investments into the rapid development of competitor treatments for immunological indications, including large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies and/or candidates under development in its current indications.
• The company is subject to various risks related to the acquisition and integration of ACELYRIN, including the effect on attracting/retaining key personnel, maintaining relationships, diversion of management attention, and unforeseen costs.
• The business is highly dependent on the success of its most advanced product candidate, envu, and there is no guarantee that envu will successfully complete development, receive regulatory approval, or be successfully commercialized.
• The regulatory approval processes of the U.S. Food and Drug Administration (FDA) and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable, and if the company is ultimately unable to obtain regulatory approval for its product candidates, its business will be substantially harmed.
• The company is dependent on the services of its management team and other clinical and scientific personnel; inability to retain or recruit additional personnel could harm the business.
• If the company is unable to obtain and maintain sufficient intellectual property protection for its product candidates, or if the scope of protection is not sufficiently broad, competitors could develop and commercialize similar products, adversely affecting the company's ability to commercialize its product candidates.
• There is no assurance that patent rights relating to inventions described and claimed in the company's or any current or future licensors' and licensees' pending patent applications will issue, or that patents based on these applications will not be challenged and rendered invalid and/or unenforceable.
• The company has and may continue to form or seek collaborations or strategic alliances or enter into licensing arrangements in the future, and it may neither enter into, nor realize the benefits of, such alliances or licensing arrangements.
• Even if regulatory approval is received, the company will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Approved product candidates could also be subject to labeling and other restrictions and market withdrawal, and the company may face penalties for non-compliance or unanticipated problems.
• Failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory schemes, standards, and other obligations related to data privacy or security (including security incidents) could harm the business, increase costs, and negatively affect operating results.
• The company may have conflicts with any current or future licensors, licensees, collaborators, or strategic partners that could delay or prevent the development or commercialization of its product candidates.
• Preliminary, top-line, and interim data from clinical trials may change as more patient data become available or are subject to audit and verification procedures, potentially resulting in material changes in the final data.
• Clinical trials conducted outside the United States may not have their data accepted by the FDA and comparable foreign regulatory authorities.
• Even if regulatory approval is received in the United States, the company may never receive regulatory approval to market outside of the United States.
• The successful commercialization of product candidates, if approved, will depend in part on the extent to which governmental authorities and health payors and insurers establish coverage, adequate reimbursement levels, and favorable pricing policies; failure to obtain or maintain these could limit marketability and revenue generation.
• The company may expend its limited resources to pursue a particular product candidate in specific indications and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• The company will need to grow its organization and may experience difficulties in managing growth and expanding operations.
• Employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the business, financial condition, results of operations, and growth prospects.
• The business entails a significant risk of product liability, and the ability to obtain sufficient insurance coverage could adversely affect the business.
• Insurance policies are expensive and only protect against some business risks, leaving the company exposed to significant uninsured liabilities.
• Strategic transactions, including acquisitions, could impact liquidity, increase expenses, dilute stockholders, and present significant distractions to management.
• The ability to use net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited due to ownership changes.
• Recent and future changes to tax laws could materially adversely affect the company.
• If information technology systems, or those used by third parties, or data are compromised, become unavailable, or suffer security breaches, the company could suffer material adverse consequences.
• Operations are predominantly concentrated in one location (California), making the company vulnerable to natural disasters.
• Projections regarding market opportunities for product candidates may not be accurate, and the actual market may be smaller than estimated.
• Cash and cash equivalents may be exposed to failure of banking institutions.
• Public opinion and scrutiny of immunology treatments may impact public perception of the company and product candidates.
• The future impairment of acquired in-process research and development (IPR&D) intangible assets related to the ACELYRIN Merger may negatively affect results of operations and financial position.
• Intellectual property rights do not necessarily address all potential threats to competitive advantage.
• The company may not identify relevant third-party patents or may incorrectly interpret their relevance, scope, or expiration.
• The company may be involved in lawsuits to protect or enforce its patents or other intellectual property, which could be expensive, time-consuming, and unsuccessful.
• The company may become involved in third-party claims of intellectual property infringement, which may prevent or delay product discovery and development efforts.
• The company may not be successful in obtaining or maintaining necessary rights to its product candidates through acquisitions and in-licenses.
• The company may become subject to claims challenging the inventorship or ownership of its or any current or future licensors' patents and other intellectual property.
• Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general.
• Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and patent protection could be reduced or eliminated as a result of noncompliance.
• Patent terms may be inadequate to protect the company's competitive position on products or product candidates for an adequate amount of time.
• If the company does not obtain patent term extension for its product candidates, its business may be materially harmed.
• If the company is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed.
• The company may be subject to claims asserting that its employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what the company regards as its own intellectual property.
• Governments outside the United States tend to impose strict price controls, which may adversely affect revenue.
• Recently enacted legislation, future legislation, and other healthcare reform measures may increase the difficulty and cost for the company to obtain regulatory approval for and commercialize its product candidates and may affect the prices it may set.
• The company's operations and relationships with healthcare providers, healthcare organizations, and third-party payors will be subject to applicable anti-bribery, anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose it to enforcement actions, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings.
• Disruptions at the FDA and other government agencies or comparable foreign regulatory authorities caused by funding shortages, government shutdowns, or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, preventing new or modified products from being developed, reviewed, approved, or commercialized in a timely manner or at all.
• An active and liquid trading market for the company's common stock may not develop, and investors may not be able to resell shares at or above the price paid for them.
• Quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts or any guidance provided, which may cause the stock price to fluctuate or decline.
• The stock price is likely to continue to be volatile, which could result in substantial losses for investors.
• Sales of a substantial number of shares of common stock could cause the stock price to fall.
• Principal stockholders and management own a significant percentage of common stock and will be able to control matters subject to stockholder approval.
• The company is an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to these statuses may make its common stock less attractive to investors.
• Anti-takeover provisions in charter documents and under Delaware law could prevent or delay an acquisition that may be beneficial to stockholders and may prevent attempts by stockholders to replace or remove current management.
• Exclusive forum provisions in organizational documents may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable.
• The board of directors is authorized to issue and designate shares of preferred stock without stockholder approval.
• The company does not anticipate paying any dividends on its capital stock in the foreseeable future, so capital appreciation, if any, will be the sole source of gain.
• The dual class structure of common stock may limit the ability to influence corporate matters and may limit visibility with respect to certain transactions.
• Unstable economic and market conditions may have serious adverse consequences on the business, financial condition, and stock price.
• If securities or industry analysts do not publish research or reports about the business, or if they publish inaccurate or unfavorable research, the stock price and trading volume could decline.
• The company incurs increased costs as a result of operating as a public company, and management is required to devote substantial time to new compliance initiatives and corporate governance practices.
• Failure to establish and maintain effective internal control over financial reporting could adversely affect the business and investor confidence.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• ACELYRIN has been named a defendant in a purported securities class action lawsuit, and the company may be the target of other securities litigation in the future.

Future Outlook

The company plans to submit an NDA for envu in PsO to the FDA in the second half of 2026 and expects to report topline results from the Phase 2 clinical trial of envu in SLE in the third quarter of 2026. It intends to expand clinical development of envu to additional therapeutic areas and indications, and to provide an update on an A-005 Phase 2 trial commencement following evaluation. The company will continue to evaluate the development program for lonigutamab and its potential differentiation in a capital efficient manner. It also aims to discover and advance earlier-stage product candidates into clinical development, leveraging its proprietary precision data analytics platform. The company expects to incur significant and increasing expenses and substantial losses for the foreseeable future as it continues development and seeks regulatory approvals and commercialization.

Management Comments

• "Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies."
• "We believe that envu is a foundational asset that exemplifies our approach."
• "We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction."
• "We plan to strategically evaluate potential partnerships to maximize the value of our lead programs and broader portfolio."
• "We believe that our product candidates, indications, clinical data and data analytics make our company an attractive partner."

Industry Context

StockSavvy.ai notes that Alumis operates in the highly competitive biopharmaceutical industry, characterized by rapid innovation and substantial investments from large pharmaceutical and biotechnology companies. The focus on Tyrosine Kinase 2 (TYK2) inhibitors places Alumis in a growing therapeutic area, with competitors like Bristol-Myers Squibb (Sotyktu/deucravacitinib) already having approved therapies. The positive Phase 3 results for envu in psoriasis are a significant step towards challenging existing treatments like apremilast and other immune-modulating agents. The expansion into neuroinflammatory diseases with A-005 and the acquisition of lonigutamab for Thyroid Eye Disease indicate a strategy to diversify the pipeline and address multiple unmet medical needs, aligning with broader industry trends towards targeted therapies over broad immunosuppression. The company's reliance on third-party manufacturers and global suppliers is common in the industry but exposes it to supply chain and regulatory risks, especially with evolving international trade policies.

Comparison to Industry Standards

• Envu's Phase 3 results in PsO (74% PASI 75, 59% sPGA 0/1 at Week 16; 65% PASI 90, >40% PASI 100 at Week 24) demonstrate strong efficacy, comparable to or potentially exceeding some existing therapies. For example, Bristol-Myers Squibb's Sotyktu (deucravacitinib), another TYK2 inhibitor, showed 58% PASI 75 and 37% sPGA 0/1 at Week 16 in its pivotal POETYK PSO-1 trial.
• The observed safety profile of envu, with the majority of AEs being mild-to-moderate and no new safety signals, suggests a potentially favorable tolerability profile compared to some first-generation allosteric TYK2 inhibitors, which have reported higher frequencies of skin rashes.
• The company's strategy of targeting TYK2, a genetically validated target, aligns with industry trends towards precision medicine, aiming for improved risk-benefit profiles compared to broad immunosuppression.
• The acquisition of lonigutamab for TED positions Alumis in a market with limited approved therapies, where Tepezza (teprotumumab) from Horizon Therapeutics is the sole currently approved treatment in the U.S. Alumis's evaluation of lonigutamab's potential differentiation in a capital-efficient manner is a prudent approach given the competitive landscape and the need to demonstrate superior safety/efficacy.
• The company's accumulated deficit of $901.9 million and continued reliance on external financing are typical for clinical-stage biopharmaceutical companies, but the recent capital raises ($324.4 million public offering and a $300 million ATM facility) indicate strong investor confidence in its pipeline and strategy.

Management Changes

Corporate Governance

Legal Proceedings

• **Boukadoum v. Acelyrin, Inc. et al. (No. 2:23-cv-09672-FMO-MAA):** A purported federal securities class action lawsuit commenced on November 15, 2023, against ACELYRIN and its then-current and former executive officers and directors. The complaint alleges violations of the Exchange Act and Securities Act by misleading investors about the Phase 2b trial of izokibep in hidradenitis suppurativa. An amended complaint was filed on March 26, 2024, and a second amended complaint was filed on February 5, 2026, after the motion to dismiss the first amended complaint was granted in January 2026. The defendants filed a motion to dismiss the second amended complaint on February 19, 2026, which is pending. Alumis assumed these liabilities in the ACELYRIN Merger.
• **Climb Bio, Inc. Dispute:** On December 31, 2025, Climb Bio, Inc. (parent company of Tenet Medicines, Inc.) filed a complaint in Delaware Superior Court seeking a declaratory judgment that budoprutug is not a Product under the Purchase Agreement, and therefore Climb Bio does not owe milestone or royalty payments to Alumis. In January 2026, Alumis issued a notice of material breach to Climb Bio for failing to timely pay a $3.0 million development milestone. Alumis disputes Climb Bio's interpretation and intends to seek recovery through litigation. The matter remains pending.

Related Party Transactions

• **2026 Public Offering:** Certain entities affiliated with Foresite Capital Management and Samsara BioCapital, LP participated in the public offering on January 7, 2026, purchasing 411,764 and 588,235 shares, respectively, at $17.00 per share.
• **Voting and Support Agreements:** Concurrently with the Merger Agreement, entities affiliated with Foresite Capital Management, AyurMaya Capital Management Fund, LP, Samsara BioCapital, LP, and Martin Babler (collectively holding approximately 62% of outstanding capital stock as of that date) entered into voting and support agreements to vote in favor of adopting the Merger Agreement and approving the issuance of shares of common stock to ACELYRIN stockholders.
• **Foresite Labs Services Agreement:** An ongoing services agreement with Foresite Labs, LLC (an affiliate of Foresite Capital Management, a holder of more than 5% of outstanding capital stock) for data and analytics services and scientific support. The company recognized $1.1 million as research and development expenses under this agreement for the year ended December 31, 2025.
• **Series C and Series C-1 Convertible Preferred Stock Financing (March and May 2024):** Entities affiliated with AyurMaya Capital Management Fund, LP, Baker Brothers Life Sciences, L.P., Foresite Capital Management, Samsara BioCapital, LP, and venBio Global Strategic Fund IV, L.P. purchased significant amounts of Series C redeemable convertible preferred stock.
• **Concurrent Private Placement (July 2024):** AyurMaya Capital Management Fund, LP (an existing holder of more than 5% of capital stock, affiliated with a director) purchased $40.0 million in shares of common stock at the IPO price in a private placement transaction.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future equity offerings (e.g., ATM facility), but also potential for increased value from successful product development and commercialization. Subject to stock price volatility and the influence of principal stockholders.
• **Employees:** Eligible for severance benefits under the Severance and Change in Control Plan upon qualifying termination. Equity incentive plans aim to attract, retain, and motivate personnel. Subject to potential workforce reductions during integration or strategic shifts.
• **Customers (future):** Aims to provide transformative medicines for immune-mediated diseases, replacing broad immunosuppression with targeted therapies, potentially offering improved outcomes and quality of life.
• **Suppliers/CMOs/CROs:** Continued reliance on third parties for manufacturing and clinical trials, subject to contractual obligations, performance risks, and potential disruptions in the supply chain.
• **Creditors:** Future debt financing may involve agreements with covenants limiting the company's ability to take specific actions, such as incurring additional debt or declaring dividends.

Next Steps

• Submit a New Drug Application (NDA) for envu in PsO to the FDA in the second half of 2026.
• Report topline results from the Phase 2 clinical trial of envu in SLE in the third quarter of 2026.
• Evaluate additional immune-mediated disease indications for envu, beyond PsO and SLE.
• Evaluate indications for the A-005 program and provide an update on a Phase 2 trial commencement.
• Continue to evaluate the development program for lonigutamab and its potential differentiation in a capital efficient manner.
• Identify and develop earlier-stage assets, including interferon regulatory factor 5 (IRF5) inhibitors.
• Strategically evaluate potential partnerships to maximize the value of lead programs and broader portfolio.
• Identify and qualify redundant manufacturers for API, drug product, and critical raw materials for all product candidates prior to NDA/MAA submissions.
• Enter into long-term master supply agreements with CMOs prior to any potential NDA submission.
• Continue to expand employee base for managerial, operational, financial, and other resources.
• Continue to improve operational, financial, and management controls, reporting systems, and procedures.
• Address the federal securities class action lawsuit against ACELYRIN and the dispute with Climb Bio, Inc.
• Comply with new UK clinical trials regulatory framework effective April 28, 2026.
• Comply with the EU Pharma Package regulations, which will reduce baseline market protection and reshape incentives.

Key Dates

Recommendation

The positive topline Phase 3 results for envu in plaque psoriasis are a significant de-risking event, demonstrating strong efficacy and a consistent safety profile, which positions the company well for an NDA submission in H2 2026. This success, combined with substantial recent capital raises ($324.4 million public offering and a $300 million ATM facility), significantly strengthens the company's financial runway and ability to advance its pipeline. While the company faces inherent risks of a clinical-stage biopharma, including ongoing losses and competition, the strong clinical data for its lead asset and robust funding provide a compelling investment thesis for long-term growth. The strategic acquisition of ACELYRIN and the diversified pipeline further enhance future potential.

Keywords

Biopharmaceutical, TYK2 inhibitor, envu, plaque psoriasis, systemic lupus erythematosus, A-005, neuroinflammation, neurodegenerative diseases, lonigutamab, Thyroid Eye Disease, clinical trials, FDA approval, SEC filing, capital raise, ACELYRIN Merger, Cantor Fitzgerald, at-the-market offering, intellectual property, biopharma, immunology, pharmaceutical development, corporate governance, risk management